FSH bioactivity was investigated through a Sertoli cell aromatase bioassay in 9 patients with gonadotropin secreting tumor, in 21 with nonfunctioning (NFPA), and 30 normal subjects. This evidence concerns the gene BRD2 and neoplasm.